GLOBRYTE: A phase 3 trial of glofitamab in people with relapsed or refractory mantle cell lymphoma

This trial is testing the medication glofitamab in people with mantle cell lymphoma (MCL) which has come after (relapsed), or not responded (refractory) to treatment.  

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT06084936
 

Trial aim and background 

The aim of this trial is to find out effective glofitamab is when given alone, in the treatment of patients with relapsed or refractory MCL. It will be compared to either:

  • Rituximab plus bendamustine
  • Lenalidomide plus rituximab

Glofitamab is a type of targeted treatment called a bispecfic antibody. This means it sticks to two different target proteins, one on the lymphoma cells, and one on healthy T cells. This helps the T cells to find the lymphoma cells and destroy them.

Who can enter 

People with relapsed or refractory MCL who have previously received a BTK inhibitor may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • Oxford Churchill Hospital, Oxford
  • Derriford Hospital, Plymouth

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06084936

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.